Last reviewed: June 25, 2026
Last updated: June 25, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Wegovy, produced average weight loss of 15% to 22% of baseline body weight in the STEP trials—but these averages mask wide individual variation. Your actual results depend on genetic factors, medication tolerance, diet quality, and activity level. Understanding the evidence helps set realistic expectations and identify strategies to maximize your outcome.
Clinical Trial Results: What the STEP Data Actually Shows
The STEP 1 trial enrolled over 1,900 adults with obesity or overweight with comorbidities and tracked weekly semaglutide injections versus placebo for 68 weeks. Participants on the highest maintenance dose (2.4 mg weekly) achieved a mean weight loss of 14.9% of baseline body weight, compared to 2.4% in the placebo group. This 12-point difference translates to meaningful metabolic improvement: reduced blood pressure, improved cholesterol profiles, and lower fasting glucose in most participants.
STEP 2 and STEP 3 extended follow-up and tested whether weight loss persists with continuous treatment. Patients who stayed on semaglutide maintained their loss for up to 2 years, while those switched to placebo regained approximately two-thirds of lost weight within a year. This pattern reveals that GLP-1 therapy works as long as you use it—stopping the medication typically leads to gradual weight rebound unless lifestyle changes remain firmly established.
Why Individual Weight Loss Ranges From 5% to 30%+
Trial averages hide significant person-to-person variation: some participants lost 5% of body weight while others exceeded 30%. This range stems from differences in baseline metabolism, insulin resistance, appetite-hormone sensitivity, and genetic factors controlling hunger signals and energy expenditure. A person with insulin resistance, for example, often sees faster initial loss and greater total reduction because semaglutide improves both appetite suppression and glucose handling simultaneously.
Adherence and dose tolerance also matter. Some individuals reach the 2.4 mg maintenance dose within 16 weeks, while others require 20 weeks or longer due to nausea, constipation, or fatigue. Research shows that patients who tolerate higher doses and maintain strict dietary compliance typically exceed trial averages. Conversely, those who experience persistent side effects or revert to old eating patterns often land below the 15% benchmark.
How Semaglutide Produces Weight Loss at the Cellular Level
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone released after eating that signals fullness to the brain's appetite centers in the hypothalamus. This mechanism reduces hunger intensity and increases satiety—so you feel satisfied on smaller meals and experience fewer cravings between eating occasions. Additionally, semaglutide slows gastric emptying (stomach-to-small-intestine movement), prolonging the sensation of fullness and reducing meal frequency.
The drug also enhances insulin secretion in response to meals while reducing glucagon release, lowering blood sugar spikes and improving metabolic stability. This combination of appetite suppression, slowed digestion, and improved blood sugar control creates a sustained calorie deficit without the constant willpower struggle typical of traditional dieting. Over months, this behavioral and metabolic shift compounds into meaningful weight reduction and improved cardiovascular health markers.
Optimizing Your Weight Loss: Genetics, Dose, and Lifestyle
Your genetic makeup influences how well you respond to semaglutide. Variants in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) affect receptor sensitivity and hormone signaling efficiency. The Precision Peptide Genetic Test offered by PlexusDx maps 14 metabolic pathways and 49 peptides linked to weight regulation, identifying whether your genetic profile suggests strong GLP-1 responsiveness, resistance to weight loss, or susceptibility to specific side effects. This personalization helps clinicians adjust dosing strategies and predict which compounds—semaglutide alone, tirzepatide, or combination therapy—may yield better outcomes for your unique biology.
Practical steps to maximize weight loss include: adopting a protein-rich diet (25–40g per meal) to sustain satiety and preserve muscle during weight loss, staying hydrated to support metabolism and reduce appetite misinterpretation, exercising 150+ minutes weekly to accelerate fat loss and improve cardiovascular benefits, and maintaining consistent meal timing to align with medication peaks. PlexusDx's compounded semaglutide injections start at $149 per month—flat pricing regardless of dose—removing financial barriers to finding your optimal dose and maintaining long-term therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How long does it take to see weight loss results on semaglutide?
Most people notice appetite reduction within 2–4 weeks of starting semaglutide, but measurable weight loss typically becomes visible after 4–8 weeks as the body adjusts to lower calorie intake. Peak results emerge around 16–20 weeks as doses escalate and lifestyle changes take root. Continued gradual loss continues through week 68 and beyond in clinical trials.
Can I achieve a 30% weight loss like some trial participants?
Yes, approximately 20–25% of STEP trial participants lost more than 20% of baseline body weight, and some exceeded 30%. Achieving this outcome depends on genetic predisposition to GLP-1 responsiveness, tolerance of higher doses without stopping, adherence to a calorie-conscious diet, and consistent physical activity. PlexusDx's Precision Peptide Genetic Test can identify whether your genetic profile predicts strong treatment response, helping optimize expectations and dosing strategies.
What happens if I stop taking semaglutide after losing weight?
STEP trials showed that participants who discontinued semaglutide regained approximately 67% of lost weight within one year. This rebound occurs because appetite hormones and hunger signals return to baseline in the absence of the medication. Long-term weight maintenance requires either continuing semaglutide indefinitely or sustaining rigorous lifestyle changes developed during treatment. PlexusDx's flat pricing model ($149/mo start) makes ongoing therapy financially accessible for those seeking durable results.
Are there side effects that could prevent me from reaching higher doses?
Nausea, constipation, vomiting, and fatigue occur in 20–40% of users, typically during dose escalation. Most side effects resolve within 1–2 weeks, but 5–10% of participants discontinue due to persistent tolerability issues. Slower dose titration, dietary adjustments (smaller meals, increased hydration), and anti-nausea strategies help many continue treatment. If side effects persist, switching to oral semaglutide or tirzepatide—both offered by PlexusDx—may improve tolerance.
How does PlexusDx personalize semaglutide treatment for better results?
PlexusDx's Precision Peptide Genetic Test ($99 add-on after month one) identifies variants in GLP1R, GIPR, FTO, and MC4R genes that predict hormone sensitivity, weight-loss potential, and side-effect risk. This genetic insight allows PlexusDx clinicians to recommend optimal dosing speed, choose between semaglutide, tirzepatide, or dual-compound therapy, and anticipate which metabolic pathways may require supplemental support—all delivered through licensed 503A compounding pharmacies across all 50 states.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Plate: What to Eat and Not Eat on Ozempic for a Smoother Journey
Phentermine vs Ozempic: Comparing Two Popular Weight Loss Medications